Reports Q1 revenue $85.9B, consensus $86.17B. “Cencora (COR) began fiscal 2026 by delivering strong financial performance and advancing our strategy through the acquisition of OneOncology,” said Robert Mauch, President and CEO of Cencora. “Our ownership of OneOncology cements our specialty MSO footprint and deepens our partnership with physicians leading in cancer care,” Mauch continued “As we continue to advance our leadership in specialty and execute our pharmaceutical-centric strategy, we are well positioned to drive continued value for all our stakeholders and deliver on our purpose.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- COR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Midday Fly By: Microsoft, Meta diverge after earnings
- First Solar downgraded, Fortinet upgraded: Wall Street’s top analyst calls
- Morgan Stanley upgrades Cencora to Overweight on specialty position
- Cencora upgraded to Overweight from Equal Weight at Morgan Stanley